



ctos[®]

2021 Annual Meeting

November 10 - 13

Vancouver Convention Centre • Vancouver, Canada

Abstract Title: PHASE 1 STUDY OF ESCALATING DOSES OF EX VIVO EXPANDED, AUTOLOTOUS NATURAL KILLER CELLS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CANCER REFRACTORY TO CONVENTIONAL THERAPY [NCT03941262]

ABSTRACT PREVIEW: PHASE 1 STUDY OF ESCALATING DOSES OF EX VIVO EXPANDED, AUTOLOTOUS NATURAL KILLER CELLS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CANCER REFRACTORY TO CONVENTIONAL THERAPY [NCT03941262]


[PHASE 1 STUDY OF ESCALATING DOSES OF EX VIVO EXPANDED, AUTOLOTOUS NATURAL KILLER CELLS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CANCER REFRACTORY TO CONVENTIONAL THERAPY \[NCT03941262\]](#)

Abstract ID: 1083133

Presentation Type: Poster

Abstract Status: Complete

Co-Author(s)



Sant P. Chawla, MD

Organization:


Sarcoma Oncology Research center

Role:

Author

CTOS Membership

Yes



Simranjit Sekhon, MD

Position:

Research Fellow

Organization:


Sarcoma Oncology Research center

Role:

Co-Author

CTOS Membership

Yes



Noufil Adnan, MD

Position:

Research Fellow

Organization:


Sarcoma Oncology Research Center

Role:

Co-Author

CTOS Membership

No



Ted T. Kim, BS

Position:

Clinical Research Coordinator

Organization:


Sarcoma Oncology Center

Role:

Co-Author

CTOS Membership

No



Victoria T. Chua-Alcala, MD

Position:

Medical Director

Organization:


Sarcoma Oncology Research center

Role:

Co-Author

CTOS Membership

Yes



Ania Moradkhani, NP

Position:

Nurse Practitioner

Organization:


Sarcoma Oncology Research center

Role:

Co-Author

CTOS Membership

No



Steven Cha, MD

Position:

Chief Medical Officer

Organization:


NKGen Biotech

Role:

Co-Author

CTOS Membership

No



Erlinda M. Gordon, MD

Position:

Director, Biological and Immunological Therapies

Organization:

Sarcoma Oncology Research Center

Role:

Co-Author

CTOS Membership

Yes

Abstract Information

Category

Immunology & Immunotherapy

Permission to Use

- Yes

Attendance

- Yes

Objective

Background and Rationale: SNK01 is an autologous natural killer (NK) cell-derived adopted cellular immunotherapy being developed as a single agent and in combination with targeted therapies to treat advanced and metastatic solid tumors. NK cells are an essential class of innate immune cells that play a critical role in mediating antitumor response. NK cells can directly kill tumor cells and rapidly secrete

proinflammatory cytokines to potentiate the adaptive immune response. SNK01 is the first-in-kind, autologous non-genetically modified NK cell therapy with highly enhanced cytotoxicity and near 100 % expression of CD16, NKG2D, NKp46, and DNAM-1, which can be consistently produced from healthy subjects, and heavily treated cancer patients alike.

Objectives:

Primary : To investigate the safety of SNK01 using NIH CT CAE vs 5.0

Secondary: To assess objective response rate (ORR), progression-free survival (PFS) using RECIST v1.1 and overall survival (OS)

Methods

In this single-arm Phase I study to investigate the safety and potential anti-tumor activity of SNK01, eleven patients (Cohorts 1-3) with refractory metastatic solid tumors were treated in a 3+ 3 monotherapy dose escalation study with five weekly infusions of SNK01 (Dose Level 1: 1×10^9 , Dose Level 2: 2×10^9 , and Dose Level 3: 4×10^9 cells/infusion). After completing the 3 Cohorts of single dose escalation of SNK01, the protocol was amended to include Cohort 4 (n=18) wherein SNK01 is given in combination with an immune checkpoint inhibitor (avelumab or pembrolizumab). Patients with PD-L1 negative or low PD-L1+tumors who have failed conventional therapy and who have measurable disease by RECIST 1.1 are being enrolled to receive either SNK01 (4×10^9 cells) + pembrolizumab 200 mg q 3 weeks or avelumab 800 mg q 2 weeks. Patients will be treated until disease progression or unacceptable toxicity. Primary end point is safety. Secondary endpoints are objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). The trial is currently in progress and 16/18 patients have been enrolled to date.

Results

The trial is currently in progress and 16/18 patients have been enrolled to date.

Conclusion

The trial is currently in progress and 16/18 patients have been enrolled to date.

Disclosure Information

FDA Disclosure

No (List the Manufacturer's Name and Drug or Device in the following question)

Manufacturer's Name and Drugs or Devices

Manufacturer: NKGen Biotech Drug: SNK01 autologous natural killer cells ex vivo expanded

Financial Relationship

No